We’re thrilled to announce the creation of our Scientific Advisory Board and Business Advisory Board. The esteemed members will support us as we continue our precision discovery efforts to identify new therapies for #IMIDs. More Information: businesswire.com/news/home/2021…

We are thrilled to announce that Evotec has made a strategic investment in IMIDomics that reflects our shared goal of leveraging data to discover and develop meaningful treatments to improve the health and quality of life of IMID patients. businesswire.com/news/home/2022…

. IMIDomics, spin-off de #VallHebron centrada en el descubrimiento y desarrollo de nuevas dianas y medicamentos para el tratamiento de enfermedades inflamatorias inmunomediadas (IMID), ha recibido una nueva inversión de capital de Evotec. Lee más: bit.ly/3pLrNHj

Proud to receive this recognition from the CataloniaBio & HealthTech. It reflects our continuous commitment to IMID patients. en.vhir.org/portal1/news-d…

IMIDomics is proud to have contributed to the early identification of #abatacept as a candidate immune modulator to reduce mortality in severe #COVID19 x.com/ToniJuliaC/sta…

📰 Las #biotech del Parc Científic de Barcelona captan 39 M€, las más destacadas: 👉 inBrain 14,3 M€ 👉 IMIDomics 16,5 M€ ✅ El vivero de la Universitat de Barcelona acoge +130 entidades y 3000 profesionales. Según el #BioRegionReport 2021, la financiación en Cataluña fue de 238 M€. Expansión Catalunya

We’re thrilled to announce the creation of our Immunology Advisory Board. The luminaries will support us refine our Precision Discovery Engine, and moving forward with identifying and pursuing targets for potential new treatments#IMIDs. businesswire.com/news/home/2022…

IMIDomics Inc. Secures Exclusive Worldwide Licensing Agreement with TNAX Biopharma Corporation for TNAX101A (IMB1001), A Promising Drug Candidate for Immune-Mediated Inflammatory Diseases businesswire.com/news/home/2023…

We are excited to announce our multi-program collaboration with Twist Bioscience to conduct antibody discovery activities against targets for patients with #IMIDs Read more: businesswire.com/news/home/2023…

Today, we announced a strategic agreement with WuXi Biologics to accelerate the development and manufacturing of IMIDomics IMB1001, a highly promising humanized antibody targeting CD226, a breakthrough target for treating #IMIDs. Read more: businesswire.com/news/home/2023…

Congratulations to Dr. Sara Marsal on receiving the Trifermed Award for Social Impact in Healthcare! awards.trifermed.com/?_gl=1%2A8f056… Dr. Marsal's remarkable dedication to the field of rheumatology and her outstanding contributions to the understanding and treatment of IMIDs.

We are excited to announce a license and collaboration agreement with Universitat de Barcelona (UB) to advance treatments of #IMIDs, developing new therapeutic approaches for two new drug targets IMB-1003 and IMB-1004. businesswire.com/news/home/2023…

Thrilled to announce Dr. Eric Perakslis as our new Senior VP & CTO, bringing stellar expertise in pharma R&D. Welcoming Dr. Ramon Felciano as a strategic advisor in biomedical AI and data science. Exciting times ahead shaping the future of IMIDomics! businesswire.com/news/home/2023…

“Today, we announced the expansion of our strategic collaboration with Bristol Myers Squibb to accelerate research and development aimed at understanding and uncovering mechanisms driving Sjögren's disease and atopic dermatitis.” businesswire.com/news/home/2023…

Pleased to announce a strategic investment in IMIDomics.🎉 Their innovative approach in developing novel medicines aligns with our mission to improve patient lives. #UCB #IMIDomics #Innovation.

We are honored and excited to announce a strategic equity investment from @UCB_News Together, we look forward to advancing novel solutions that address the unmet needs of patients suffering from #IMIDs. Read more here: ucb.com/stories-media/…

We are thrilled to announce that respected Matthias Evers, Ph. D., will join the IMIDomics Board of Directors effective October 1, 2024. Dr. Evers' significant expertise and insights will be critical as we advance our mission of delivering breakthrough medicines for IMIDs.

Thrilled to be recognized in @UCB_news’ 2024 Annual Report! Our collaboration is driving innovation in IMID research, developing targeted therapies for immune-mediated inflammatory diseases. #Biotech #IMID #Collaboration #UCB #PrecisionMedicine

Exciting news! We have partnered with @FormationBio to advance our first-in-class anti-CD226 monoclonal antibody program for #autoimmunediseases. This collaboration marks a key step in our mission to bring innovative treatments to patients currently underserved by existing IMID

What's the future of #autoimmunedisease treatment? Our partnership with @FormationBio aims to answer that question! Check out our latest video featuring Fred Craves discussing the collaboration & its potential impact on #autoimmunedisease treatment #drugdiscovery